ERBB2 and breast carcinoma: Meanwhile, trastuzumab‐duocarmazine (SYD985) has also exhibited notable therapeutic activity in HER2‐low breast cancer patients with an objective response rate of 31.9% (ClinicalTrials.gov identifier: NCT02277717).15